Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors

BACKGROUND: Targeted therapies are becoming an essential part of breast cancer treatment and agents targeting the type I insulin-like growth factor receptor (IGF-IR) are currently being investigated in clinical trials. One of the limitations of targeted therapies is the development of resistant vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Craig I, Moorehead, Roger A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254084/
https://www.ncbi.nlm.nih.gov/pubmed/22070644
http://dx.doi.org/10.1186/1471-2407-11-480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254084/
https://www.ncbi.nlm.nih.gov/pubmed/22070644
http://dx.doi.org/10.1186/1471-2407-11-480

Ejemplares similares